VJHemOnc is committed to improving our service to you

ASH 2019 | FIBROMET preliminary results: metformin promising for primary MF

VJHemOnc is committed to improving our service to you

Sara Olalla Saad

Sara Olalla Saad, PhD, University of Campinas & Hemocentro – Unicamp, Campinas, Brazil, discusses the preliminary results from an open label phase 2 trial, FIBROMET, evaluating the effects of metformin on bone marrow fibrosis and disease progression in primary myelofibrosis (PMF) patients. Prof. Saad highlights how this re-use of an old drug would give a cheaper and more accessible treatment, and outlines the next steps for the study. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter